Related references
Note: Only part of the references are listed.Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud et al.
LANCET ONCOLOGY (2019)
Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma
Bo Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice
Mao-Chi Weng et al.
BIOSCIENCE REPORTS (2018)
Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
Liyan Du et al.
MOLECULAR MEDICINE REPORTS (2018)
Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-κB Activation
Kun-Ching Lee et al.
IN VIVO (2018)
lncRNA LINC01296 regulates the proliferation, metastasis and cell cycle of osteosarcoma through cyclin D1
Xin Yu et al.
ONCOLOGY REPORTS (2018)
Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma A meta-analysis of 16 studies
Jian Zhou et al.
MEDICINE (2018)
Benzyl isothiocyanate (BITC) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer CAR cells
Chiu-Fang Lee et al.
BIOMEDICINE-TAIWAN (2018)
Magnolol Induces Apoptosis and Inhibits ERK-modulated Metastatic Potential in Hepatocellular Carcinoma Cells
Lin-Yen Kuan et al.
IN VIVO (2018)
Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells
Jai-Jen Tsai et al.
ONCOLOGY REPORTS (2017)
Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells
Yi Zhang et al.
EXPERIMENTAL CELL RESEARCH (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells
I-Tsang Chiang et al.
ANTICANCER RESEARCH (2017)
A Single Nucleotide Polymorphism (rs1056629) in 3 '-UTR of MMP-9 is Responsible for a Decreased Risk of Metastatic Osteosarcoma by Compromising its Interaction with microRNA-491-5p
Xiaodong Tian et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Future directions in the treatment of osteosarcoma
Michael W. Bishop et al.
CURRENT OPINION IN PEDIATRICS (2016)
miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
Pablo Berlanga et al.
MOLECULAR ONCOLOGY (2016)
PI3K/Akt signaling in osteosarcoma
Jian Zhang et al.
CLINICA CHIMICA ACTA (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis
Liliana Endo-Munoz et al.
PLOS ONE (2015)
被撤回的出版物: Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin (Retracted article. See vol. 47, 2022)
Yang Qu et al.
ONCOLOGY REPORTS (2015)
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Emmy D. G. Fleuren et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma
Sebastien Salas et al.
BMC CANCER (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Translational biology of osteosarcoma
Maya Kansara et al.
NATURE REVIEWS CANCER (2014)
Expression of c-FLIP in Pulmonary Metastases in Osteosarcoma Patients and Human Xenografts
Krithi Rao-Bindal et al.
PEDIATRIC BLOOD & CANCER (2013)
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
Kosei Ando et al.
Cancers (2013)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Role of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection
M. Krzyzowska et al.
CELL DEATH & DISEASE (2011)
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Ymera Pignochino et al.
MOLECULAR CANCER (2009)
Detection of apoptosis induced by new type gosling viral enteritis virus in vitro through fluorescein annexin V-FITC/PI double labeling
Shun Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members
Min Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
John P. Alao
MOLECULAR CANCER (2007)
Share Paper
